4//SEC Filing
Fickenscher James E 4
Accession 0001062993-22-016556
CIK 0001621443other
Filed
Jul 19, 8:00 PM ET
Accepted
Jul 20, 4:05 PM ET
Size
1.8 MB
Accession
0001062993-22-016556
Insider Transaction Report
Form 4
Fickenscher James E
Chief Financial Officer
Transactions
- Award
Common Stock
2022-07-18+20,800→ 178,518 total - Sale
Common Stock
2022-07-19$1.10/sh−6,013$6,614→ 172,505 total
Footnotes (2)
- [F1]On July 18, 2022, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 20,800 performance-based restricted stock awards granted in a prior year.
- [F2]This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.
Issuer
Zynerba Pharmaceuticals, Inc.
CIK 0001621443
Entity typeother
Related Parties
1- filerCIK 0001327442
Filing Metadata
- Form type
- 4
- Filed
- Jul 19, 8:00 PM ET
- Accepted
- Jul 20, 4:05 PM ET
- Size
- 1.8 MB